| Developers: | Promomed |
| Date of the premiere of the system: | 2024/10/04 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
Main article: Obesity
2024: Beginning of registration of "Velgiya"
On October 4, 2024, Promomed PJSC announced the completion of the registration procedure for Velgia for the treatment of overweight and obesity of any severity.
The first batches of Velgia Group will be released into civil circulation in the 4th quarter of 2024. The sale of the drug through a commercial sales channel will ensure the wide availability of the drug for patients.
The drug Velgiya was created purposefully for the treatment of overweight and obesity - a non-infectious pandemic of our time, which has already covered more than half of the population of our country and the world. Velgia contains specially selected concentrations and increased dosages of the active substance, which increases its therapeutic effectiveness. The drug significantly reduces weight and contributes to the correction of metabolic disorders that underlie the formation of a number of cardiovascular and oncological diseases - the main causes of mortality in our country.
The launch of the drug for the treatment of overweight and obesity continues to implement its strategy presented as part of the initial placement of securities in July 2024 and aimed at strengthening its position in the most promising, volumetric and rapidly growing segments of the pharmaceutical market.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |